미네랄리스 테라퓨틱스(MLYS) 2026년 3분기 실적 발표 콘퍼런스콜: 로룬드로스타트 FDA 결정 임박

핵심 요약

• 미네랄리스 테라퓨틱스(Mineralys Therapeutics)는 로룬드로스타트(lorundrostat)의 처방의약품 신청자 수수료법(PDUFA) 목표 심사일인 2026년 12월 22일을 앞두고 있다. 경영진은 출시 준비가 막바지 단계에 접어든 가운데 미국 식품의약국(FDA)의 심사가 정상적으로 진행되고 있다고 밝혔다.
• 임상 3상 Launch-HTN 분석에서 로룬드로스타트 50mg 투여군의 46%가 진료실 수축기 혈압 130mmHg 미만을 달성했으며, 3분의 2 이상은 최소 10mmHg 이상의 혈압 강하를 기록했다.
• 2026년 9월 30일 기준 현금, 현금성 자산 및 투자자산은 총 6억 2,470만 달러로 집계됐다. 경영진은 이 자금을 바탕으로 로룬드로스타트의 잠재적 상용화 출시를 포함한 계획된 사업 운영을 2028년까지 지속할 수 있을 것으로 전망했다.
• 2026년 3분기 순손실은 전년 동기의 3,690만 달러에서 5,730만 달러로 확대됐으며, 이는 주로 상용화 관련 일반관리비 지출 증가를 반영한 결과다.
• 현장 영업팀 구축이 완료됐으며, 영업 인력의 업계 경력은 평균 약 15년이다. 보험사와의 협의는 현재 미국 전체 피보험자의 대다수를 포괄하고 있다.
• 경영진은 최소 2종 이상의 항고혈압제를 복용 중인 미국 성인 중 약 2,000만 명이 여전히 목표 혈압에 도달하지 못한 것으로 추산하며, 이를 로룬드로스타트의 주요 상업적 기회로 규정하고 있다.

주요 재무 데이터

연구개발비는 2025년 2분기 로룬드로스타트의 핵심 임상 프로그램이 종료됨에 따라 전임상 및 임상 비용이 850만 달러 감소한 영향 등으로 줄었다. 임상 시약 공급, 제조, 규제 관련 비용 및 기타 비용도 30만 달러 추가로 감소했다.

일반관리비는 전문 서비스 수수료가 1,540만 달러 증가하고 인건비 관련 비용이 1,140만 달러 증가함에 따라 늘어났다. 기타 관리비용도 90만 달러 증가했다.

사업 및 운영 실적

로룬드로스타트는 미네랄리스의 핵심 가치 동력으로 남아 있다. 이 신약 후보물질은 조절되지 않거나 치료 저항성을 보이는 고혈압 치료제로 심사를 받고 있으며, FDA의 결정 목표일은 2026년 12월 22일이다.

12주간 진행된 Launch-HTN 분석에서 참가자들은 2~5종의 항고혈압제를 복용하고 있음에도 조절되지 않거나 치료 저항성을 보이는 고혈압을 앓고 있었다. 로룬드로스타트 50mg 투여 결과 참가자의 46%가 진료실 수축기 혈압 130mmHg 미만에 도달했으며, 3분의 2 이상은 최소 10mmHg 이상의 혈압 강하를 달성했다.

미네랄리스는 중등도에서 중증의 폐쇄성 수면무호흡증 및 고혈압을 앓고 있는 과체중 또는 비만 성인을 대상으로 한 임상 2상 Explore-OSA의 최종 결과도 발표했다. 4주 차에 로룬드로스타트 50mg을 저녁에 투여한 결과 아침 수축기 혈압이 11.1mmHg 감소한 반면, 위약군은 1.0mmHg 감소에 그쳤다. 해당 임상에서 무호흡-저호흡 지수(AHI)에는 유의미한 변화가 나타나지 않았다. 경영진은 고칼륨혈증을 포함한 중대한 안전성 문제가 발생하지 않아 안전성과 내약성이 양호했다고 설명했다.

Transform-HTN 공개 라벨 연장 연구의 장기 유효성 및 안전성 데이터는 2026년 11월 8일 미국심장협회(AHA) 학술대회에서 발표될 예정이다.

상용화 준비는 완료 단계에 가까워지고 있다. 미네랄리스는 현장 영업 인력 채용을 마쳤고, 의학부 및 의학학술연계(MSL) 역량을 확대했으며, 미국 전체 피보험자의 대다수를 대표하는 보험사들과 협의를 진행했다. 또한 의사, 병원 직원 및 환자를 위한 환자 지원 프로그램도 마무리 중이다.

경영진 가이던스

경영진은 회사가 보유한 6억 2,470만 달러 규모의 현금, 현금성 자산 및 투자자산으로 로룬드로스타트의 잠재적 상용화 출시를 포함한 계획된 사업 운영을 2028년까지 감당할 수 있을 것으로 보고 있다.

로룬드로스타트가 승인될 경우 미네랄리스는 가능한 한 조속히 제품을 출시할 방침이나, 경영진은 승인 후 출시까지의 구체적인 기간을 명시하지는 않았다. 약가, 총매출 대비 순매출(gross-to-net) 가정치 및 출시 성과 지표는 승인 이후 또는 상용화 시점에 임박해 다뤄질 것으로 예상된다.

경영진은 초기 보험 적용은 민간 상업보험이 주도할 것으로 예상하고 있다. 메디케어(Medicare)의 경우 예외 절차를 통해 접근성이 시작된 후, 처방집 등재 범위가 넓어짐에 따라 확대될 수 있을 것으로 보인다.

리스크 및 주목할 점

• 로룬드로스타트는 2026년 12월 22일 PDUFA 목표 심사일을 기준으로 여전히 FDA 심사 대상이다. 경영진은 규제 당국과의 논의가 정상적으로 진행되고 있다고 설명했다.
• 초기 환자 접근성은 민간 상업보험에서 더 강하게 나타날 것으로 예상되는 반면, 메디케어 급여는 처방집 등재가 확대되기 전까지 건별 예외 승인 절차를 거쳐야 할 수 있다.
• 약가, 리베이트 전략 및 총매출 대비 순매출(gross-to-net) 구조는 출시 경제성의 중요한 변수로 남아 있다.
• Explore-OSA 임상에서는 혈압 강하 효과가 입증되었으나, 무호흡-저호흡 지수(AHI)에서는 유의미한 개선을 보이지 못했다.
• 미네랄리스가 상용화 인프라를 구축함에 따라 일반관리비가 급증했으며, 이는 분기 순손실 확대로 이어졌다.
• 고혈압 이외의 로룬드로스타트 적응증 확대 계획과 잠재적 파트너십 추진 여부는 여전히 검토 중이다.

애널리스트 질의응답(Q&A) 주요 내용

경쟁 구도 및 시장 입지: 경영진은 박스드로스타트(baxdrostat)의 초기 도입을 조절되지 않는 고혈압 및 저항성 고혈압 환자군에서 알도스테론 합성효소 억제제에 대한 수요가 입증된 것으로 보았다. 신규 처방 환자 1만 2,000명 달성과 1차 진료의 및 전문의 모두의 처방 사례를 언급하는 한편, 로룬드로스타트의 혈압 강하 효과, 선택성, 반감기 및 안전성 프로파일을 강조했다.

보험 적용 및 접근성: 미네랄리스는 이미 보험사들과 논의를 시작했으며, 향후 승인 후 신속한 협의가 진행될 것으로 기대하고 있다. 경영진은 환자 지원 프로그램이 의사, 병원 직원 및 환자가 민간 보험 적용과 메디케어 예외 승인 절차를 원활히 진행하는 데 도움이 될 것이라고 밝혔다.

진료 지침 등재: 경영진은 알도스테론 합성효소 억제제가 초기에는 4차 치료제 단계의 저항성 고혈압 환경에 먼저 포함될 수 있을 것으로 예상하고 있다. 가이드라인이 보험사의 결정에 참고가 되겠지만 보험 급여를 결정하는 유일한 요인은 아닐 것으로 보고 있다.

GLP-1 제제와의 경쟁: 경영진은 로룬드로스타트가 정상 체중, 과체중 및 비만 환자 전반에 걸쳐 일관된 혈압 강하 효과를 나타냈다고 밝혔다. 또한 비만 치료제와 로룬드로스타트는 상호 배타적이기보다는 상호 보완적인 관계가 될 수 있다고 설명했다.

추가 적응증 및 파트너십: 미네랄리스는 고혈압 이외의 분야에서 로룬드로스타트 개발 가능성을 지속적으로 검토하고 있으며, 환자 접근성을 확대할 수 있는 파트너십에 대해 열린 입장을 유지하고 있으나 경영진은 구체적인 계획이나 시점을 밝히지 않았다.

실적 발표 컨퍼런스콜 전문

전체 실적 발표 컨퍼런스 콜 녹취록

경영진 발표

Operator

Greetings. Welcome to the Mineralys Therapeutics Third Quarter 2026 Conference Call. [Operator Instructions] Please note, this conference is being recorded.

It is now my pleasure to introduce your host, Dan Ferry of Lifesci Advisors. Please go ahead, sir.

Daniel Ferry

Thank you. I would like to welcome everyone joining us today for our third quarter 2026 conference call.

This afternoon, after the close of market trading, we issued a press release providing our third quarter 2026 financial results and business updates. A replay of today's call will be available on the Investors section of our website approximately 1 hour after its completion. After our prepared remarks, we will open the call for Q&A.

Before we begin, I would like to remind everyone that this conference call and webcast will contain forward-looking statements about the company. Actual results could differ materially from those stated or implied by these forward-looking statements due to risks and uncertainties associated with the company's business. These forward-looking statements are qualified by the cautionary statements contained in today's press release and our SEC filings, including our annual report on Form 10-K and subsequent filings. Please note that these forward-looking statements reflect our opinions only as of today, November 4, 2026. Except as required by law, we specifically disclaim any obligation to update or revise these forward-looking statements in light of new information or future events.

I would now like to turn the call over to Jon Congleton, Chief Executive Officer of Mineralys Therapeutics.

Jon Congleton

Thank you, Dan. Good afternoon, everyone, and welcome to our third quarter 2026 financial results and corporate update conference call.

We've had an exciting and productive quarter, and I look forward to sharing our update. Today, I'm joined by Adam Levy, our Chief Financial Officer; and Eric Warren, our Chief Commercial Officer. I'll begin with an overview of the business and our recent clinical progress. Eric will then provide a commercial update, and Adam will review our third quarter financial results before we open the call for your questions.

We are now just weeks away from our PDUFA target date of December 22. While the FDA continues its review of the NDA, our focus is on completing our launch preparations so that we are ready to reach patients soon after the potential approval of lorundrostat. Approximately 20 million adults with hypertension treated with 2 or more drugs fail to achieve their blood pressure goal. The implications are clear. If people with hypertension can achieve their blood pressure goals, they are less likely to have poor outcomes that impact their quality of life and longevity. Providing innovations to help people achieve their blood pressure goals is what drives our work every day. A critical part of that work is the publication and presentation of lorundrostat data for the medical community to build awareness, understanding and enthusiasm for its clinical profile.

The major medical meetings this fall are giving us a series of opportunities to present data on lorundrostat that highlight its differentiated profile. We recently presented new data at the AHA Hypertension Scientific Sessions and at ASN Kidney Week, and we have an important late-breaking presentation coming this Sunday at the American Heart Association Scientific Sessions. We believe the data we have presented to date add to the strength of the data from our clinical program and suggest the potential of lorundrostat to help patients with difficult-to-treat hypertension reach their guideline recommended systolic blood pressure goals. These data include a new analysis of our pivotal Phase III Launch-HTN trial.

Participants in Launch-HTN had uncontrolled or treatment-resistant hypertension despite being treated with 2 to 5 antihypertensive therapies. In this 12-week analysis, 46% of participants treated with lorundrostat 50 milligrams achieved the AHA/ACC guideline-recommended office systolic blood pressure target of less than 130 millimeters of mercury and more than 2/3 achieved a systolic blood pressure reduction of at least 10 millimeters of mercury. We believe these are compelling data in a population that had previously not been able to reach their goal with existing therapies.

We also presented the final results from our Phase II Explore-OSA trial in overweight or obese adults with moderate to severe obstructive sleep apnea and hypertension. As many as 70% to 80% of adults with resistant hypertension have OSA. Their nighttime blood pressure is often elevated and is considered a significant driver of cardiovascular risk. In Explore-OSA, lorundrostat 50 milligrams taken once daily in the evening, reduced morning systolic blood pressure by 11.1 millimeters of mercury at week 4 compared with a 1.0 millimeter mercury reduction with placebo. Although we did not observe a measurable change in the Apnea-Hypopnea Index, the blood pressure reduction was consistent with what we saw in our pivotal trials and the safety and tolerability profile was favorable with no evidence of serious safety events, including hyperkalemia. We believe these results further emphasize the potential of lorundrostat in a high-risk subpopulation in whom blood pressure is particularly difficult to control.

New long-term efficacy and safety data from our ongoing Transform-HTN open-label extension trial will be featured in a late-breaking scientific presentation at the American Heart Association Scientific Sessions 2026 on November 8 in Chicago. Durable blood pressure control and a well-characterized long-term safety profile are important considerations for physicians managing a chronic condition like hypertension. We look forward to sharing these data with the medical community. As we have discussed, aldosterone plays a central role in hypertension as well as other cardiorenal and metabolic disorders. We remain committed to advancing our work in aldosterone-driven disease states and are evaluating the next steps in the clinical development of lorundrostat. Once we have finalized those plans, we will share them with you.

We're also excited to have 2 new Board members join Mineralys as we prepare for the launch of lorundrostat. Kris Peterson and Lonnel Coats are 2 experienced executives that bring a wealth of commercial expertise to Mineralys at this juncture of our corporate life. They will be providing their insights, perspective and experience to our management team as we prepare the market, the asset and the company for commercialization. As a part of this transition, Derek DiRocco, who joined the Board while we were a private company, will be concluding his tenure at the end of this year. I want to thank Derek for his support and guidance over the past several years during our development stage.

With that, I'll turn the call over to Eric to provide a commercial update.

Eric Warren

Thank you, Jon.

Our commercial organization continues to execute against our launch preparation plans, and we are advancing through the final stages of launch readiness. We believe we are well positioned to support awareness, drive adoption and create favorable access soon after potential approval.

Let me begin with the opportunity. As Jon noted, approximately 20 million adults in the U.S. are living with uncontrolled or resistant hypertension, representing a large and underserved population with meaningful clinical need. Our commercial focus is on clearly communicating the potential value of lorundrostat for appropriate patients relative to existing treatment options including its potential to improve blood pressure control, help more patients reach treatment goals and to do so with a safety profile supported by our clinical data package.

From an execution standpoint, I am pleased to report that our field sales team is now in place. In addition to our seasoned commercial leadership team, we have hired sales representatives with an average industry tenure of approximately 15 years. We have also continued to strengthen our medical affairs and medical science liaison capabilities. As Jon mentioned, our engagement with leading hypertension experts remains active with a focus on education around the unmet need in uncontrolled or resistant hypertension.

On the market access front, our engagement with payers now extends to the majority of U.S. covered lives. Our discussions continue to center on the clinical and economic burden of uncontrolled hypertension and the value proposition supported by lorundrostat's clinical data package. These conversations continue to reinforce our view that payers recognize the unmet need in this patient population. In parallel, we are finalizing a full-service patient support program designed to help physicians, their office staff and patients navigate access efficiently.

Our brand marketing efforts are also well underway, building the launch campaign we described last quarter, which is designed to educate both health care providers and patients. Taken together, we believe these efforts reflect launch readiness across the organization. We have built the team, advanced payer and provider engagement, expanded our educational infrastructure and put the core launch capabilities in place to support the introduction of lorundrostat if approved. We remain encouraged by feedback we are receiving from physicians, payers and patients, and we believe Mineralys is well positioned for launch.

With that, I'll turn the call over to Adam to review our third quarter financial results.

Adam Levy

Thank you, Eric. Good afternoon, everyone.

Today, I will discuss select portions of our third quarter 2026 financial results. Additional details can be found in our Form 10-Q, which will be filed with the SEC today. We ended the quarter with cash, cash equivalents and investments of $624.7 million as of September 30, 2026, compared to $656.6 million as of December 31, 2025. We believe that our current cash, cash equivalents and investments will be sufficient to fund our planned operations, including the commercial launch of lorundrostat into 2028.

R&D expenses for the quarter ended September 30, 2026, were $22.7 million compared to $31.5 million for the quarter ended September 30, 2025. The decrease in R&D expenses was primarily due to $8.5 million of lower preclinical and clinical costs resulting from the conclusion of the lorundrostat pivotal program in the second quarter of 2025 and $0.3 million of decreased clinical supply, manufacturing, regulatory and other costs.

G&A expenses were $37.4 million for the quarter ended September 30, 2026, compared to $9.7 million for the quarter ended September 30, 2025. The increase in G&A expenses was primarily due to investments to expand our operations in preparation for commercialization, including $15.4 million of higher professional fees, $11.4 million of increased personnel-related expenses resulting from headcount growth and increased compensation and $0.9 million of increased other administrative expenses.

Total other income net was $2.8 million for the quarter ended September 30, 2026, compared to $4.2 million for the quarter ended September 30, 2025. The decrease was primarily due to $3.2 million of increased interest expense related to the senior secured term loan entered into in June 2026, partially offset by $1.8 million of increased interest earned on investments as a result of higher average cash balances.

Net loss was $57.3 million for the quarter ended September 30, 2026, compared to $36.9 million for the quarter ended September 30, 2025. The increase was primarily attributable to the factors impacting our expenses that I described earlier.

With that, I will ask the operator to open the call for questions. Operator?

Operator

[Operator Instructions] Our first question is from Richard Law with Goldman Sachs.

질의응답

Jin Law

Congrats on the progress. A couple of questions for me. The first is, how do you think about BAXFENDY's launch results so far with that $9 million revenues in Q3? And then the comment about payer coverage and not expecting Medicare coverage until 2028. Did anything stood out to you? And anything that you can see can be done differently and improved on as a second to market player? And I have a couple more follow-ups.

Jon Congleton

Yes, Rich. Thanks for the question. I appreciate it. I think at a high level, and I'll have Eric give you some more color, but at a high level, I think we're reviewing the baxdrostat launch is a validation of what we've been talking about that the demand is out there for ASIs to address this uncontrolled and resistant hypertension population and that access or coverage is out there as well. So I think it's validating those assumptions, but I'll have Eric add some additional color.

Eric Warren

Yes. Thanks, Rich. So as you know, Q3 was the first full quarter for them. So it is still really early. And we don't have any visibility into their rebates and buydowns. So it's difficult to form any kind of GTN correlations. But the initial prescription trends look favorable. 12,000 new patient starts is encouraging. I was also encouraged to see both primary care as well as specialists prescribing and the use in both resistant as well as uncontrolled hypertension. And as you mentioned, most of the business is coming from commercial, but they are getting some Medicare reimbursement now through that exception process that we've talked about. And that's why we deployed our account management team in the first quarter of this year to get an early jump on that payer engagement. We've been completing PI discussions with the vast majority of payers and lives. And we also have that patient support program that I commented on during my opening remarks that are going to make a big difference for us, Rich.

Jin Law

Okay. Got it. And then what are the development plans for lorundrostat beyond hypertension? Like which indication is the top priority that will potentially be the next Phase III in development?

Jon Congleton

Yes, Rich, thanks for that. We're obviously very enthusiastic about lorundrostat. We feel that aldosterone plays a significant role in driving not only hypertension, but frankly, comorbidities related to hypertension. We haven't provided clarity on that yet. We're continuing to evaluate it. And once we've locked in on a plan, we'll be sure to share that with the marketplace.

Jin Law

I got it. And just one last question to squeeze it in. I know we've been talking about partnership for some time. Is some form of partnership deal still on the table ahead of the upcoming launch?

Jon Congleton

Yes. Rich, we're always interested in getting lorundrostat to as many patients as we can. Partnering may be an aspect of that. And so we're routinely evaluating that. We're really not in a position to expand on specific activities at this time, though.

Operator

The next question is from Michael DiFiore with Evercore ISI.

Michael DiFiore

Congrats on the progress. Just 2 for me. If you give any initial thoughts you could share on the pricing versus access trade-off that you're optimizing for? In other words, would you accept a meaningfully lower net price in order to secure broad nonexclusive access? And my second question is regarding the launch. I mean, will you allow the reporting of prescription data at launch? And if not, which metrics will be provided to inform progress?

Jon Congleton

Yes. Mike, I appreciate the call. As we've stated in the past, pricing is something that we'll communicate as well as our thoughts on access and gross to net sometime post approval, post launch. Our goal is really to ensure that when physicians and patients decide that lorundrostat is the right choice for them that they have access to that. Part of that is price, part of that is the rebate strategy and part of it is what Eric described as the patient support program. As it relates to metrics that we'll provide at launch, presuming approval, I think it's premature to speak to that at this point. We'll certainly provide that. I would suggest post approval and likely subsequent to launch, but we'll try to provide visibility. We've tried to be transparent in the past as appropriate. I just don't think this is the time right now.

Operator

The next question is from Jason Gerberry with Bank of America.

Dina Ramadane

This is Dina on for Jason. Congrats on the progress this quarter. Just 2 quick ones from us. If BaxPA is positive next year and then you get first mover evidence in the primary aldosteronism, do you see that primarily expanding awareness of the aldosterone biology and benefiting the entire ASI class? Or is there a point where molecule-specific evidence begins to create a competitive advantage for BAXFENDY? And what would lorundrostat need to do to prevent that? And then just a quick question on kind of the label discussions you're having with FDA. We're now in 5, 7 weeks of the PDUFA and without getting ahead of the agency, have your label and post-marketing conversations progressed in line with your expectations? And has anything changed in your view of the likely breadth of the label or post-marketing requirements?

Jon Congleton

Thanks, Dina. We're obviously very much focused right now on the NDA review with the agency. I would say the dialogues are proceeding at normal course. I would say we continue to anticipate FDA feedback on December 22 on the PDUFA. As it relates to primary aldosteronism, I think there's a lot of thinking that's evolved over the 6 years I've been involved with Mineralys that dysregulated aldosterone is really more of a spectrum as opposed to defined disease states. Obviously, it will be interesting to see that data.

I think we've built out a very broad and diverse data set with lorundrostat, beginning with the proof-of-concept trial through our 2 pivotal studies in both apparent and confirmed hypertension as well as in our Explore programs looking at comorbid conditions such as CKD and OSA. So we feel very comfortable with the profile that's emerged with lorundrostat. How physicians view accumulating data and what is viewed as class effect and what is viewed as specific. I think it's a fair question. I think part of that will evolve over time, but we're obviously very focused on the 20 million patients right now that are struggling to get to goal. We know the implications if they do not. And we think that's where the imminent near-term opportunity is presuming approval of lorundrostat.

Operator

Our next question is from Evan Wang with Guggenheim Securities.

Boran Wang

This is Evan Wang. I'm here for Seamus Fernandez at Guggenheim. Just one from us. Curious, just given the feedback from AstraZeneca on Medicare, curious how you're thinking about how important Medicare is? And do you see this as an opportunity to really level the playing field with AstraZeneca in terms of time lines? And are there any other considerations from the AstraZeneca side that could impact lorundrostat's opportunity to compete?

Jon Congleton

Evan, do me a favor. Can you repeat the second half of your question? I got the first part.

Boran Wang

I was curious if there's anything like bundling wise, AstraZeneca could do that could negatively impact lorundrostat's ability to compete.

Jon Congleton

Yes. Evan, thanks for the question. As Eric indicated, we've been obviously watching the baxdrostat uptake. We think it does reflect demand from a physician standpoint to address those patients that are uncontrolled and resistant as well as access. We've gotten questions in the past about missing the bid cycle as AstraZeneca did. Presuming we get approved, we won't hit that bid cycle as well, whether or not patients on Medicare will get access. They clearly will. We know hypertension affects a significant amount of patients that are Medicare eligible as far as their coverage. And so we'll be looking forward to expanding that as soon as it's accepted on the formulary, but it doesn't preclude patients getting access to it. And so that's part of where we'll continue to focus, presuming approval at launch.

If I heard the last part of your question as far as just competitive dynamics, I think one of the points I'd like to make is that, yes, there's some natural competitive dynamics between lorundrostat and baxdrostat and some distinct differences within the data sets. But I think fundamentally, our focus is on the 20 million patients, less so on baxdrostat. I think if we got distracted and just thought about comparisons across ASIs, we're missing the broader opportunity. The market, I think, is primed at this point for an aldosterone-directed therapy that physicians can utilize with really robust clinically meaningful blood pressure reduction and doing so with a nice safety and tolerability profile. And so that's where our focus is really on as we're building out our commercial readiness presuming approval.

Operator

Our next question is from Mohit Bansal with Wells Fargo.

Mohit Bansal

Congrats on all the progress as well from my side. So Jon, I want to divert it to -- I want to talk a little bit about the segmentation of the market a little bit here. Trying to understand in the resistance as well as uncontrolled hypertension, what proportion of the patients are overweight or obese? And I think the related question is that we'll probably see Foundayo data next year for hypertension. And I think they are going after 25 and higher BMI. So it does look like GLP-1s actually lower the blood pressure as well. So like how do you see the market evolving with your drug and also GLP-1s going in there for the segment of the patients who are overweight and obese?

Jon Congleton

Yes, Mohit. Thank you for your question. And look, at the end of the day, it's really exciting times, I think, for patients dealing with cardiorenal metabolic disorders. We're seeing innovations just in the last several years that are making meaningful impact on their lives. We have clearly studied the benefit of lorundrostat in patients, whether they're normal BMI, overweight or obese, we've seen across that spectrum, very consistent reductions in their blood pressure. Clearly, you're seeing blood pressure reductions with weight loss, whether it's GLP-1 or some other means.

Typically, it's been about 5 millimeters of mercury, which is beneficial to patients, but certainly not in the realm of what we've seen both in absolute figures of 15 to 19 millimeters of mercury between advance and launch or even the placebo-adjusted figures of 8 to 11.7 -- 11.6, sorry. I don't know that one precludes the other. Clearly, there will be some patients that may be super responders on a GLP-1, but I think the vast majority of patients will likely need the continued benefits of therapeutic like lorundrostat. And as you know, Mohit, we believe there is a tight correlation between that visceral adiposity and dysregulated aldosterone. And so for those patients, hopefully, they see good weight loss, but they likely will still have some level of visceral adiposity as well as elevated systolic BP. So we think there's actually some synergy there.

Operator

Our next question is from Rami Katkhuda with LifeSci Capital.

Rami Katkhuda

I guess building off a few previous questions, how quickly do you anticipate achieving broad payer coverage post launch? And how should we think about the payer mix across resistant and uncontrolled hypertension patients? And then secondly, are there any historical CV drug launches that you view as relevant comps for lorundrostat, particularly about the time it could take to reach peak sales?

Jon Congleton

Rami, let me have Eric address the first part, and I'll grab the second part of your question.

Eric Warren

Yes. So from a payer coverage perspective, Rami, so definitely commercial will lead the way in terms of providing that access or that coverage initially. But we will, and we do anticipate Medicare coverage through the exception process, as I mentioned on a prior response. The Medicare exception process typically looks at the label, but it does require some navigation of that in which the PSP that we put forward is designed to support that. So commercial will lead the way, but don't discount Medicare from the beginning because we will get that through the exception process. We'll see progressive increases in that Medicare and expect a pretty equal contribution as we get to steady state.

Jon Congleton

And Rami, as far as analogs, I think we're living it right now. I think the baxdrostat launch, again, we've characterized that as very encouraging, encouraging on the validation of the demand and the access. So we're comforted by that. And I think there's even some signals of that with the oral PCSK9 that was reported recently by Merck. So there's clearly a need within cardiorenal metabolic disorders for the kind of innovations that have come forward in the last several years, and we're excited to be a part of that.

Operator

Our next question is from Tara Bancroft with TD Cowen.

Tara Bancroft

I have a similar kind of question, but I'm curious then, I didn't hear in that response anything about guidelines. So maybe you could talk about how you think guideline inclusion will play out, both for lorundrostat and in terms of the competitive dynamics of baxdrostat too. Like how soon do you think you could get the guideline inclusion? And how important are guidelines for payer coverage and formulary inclusion?

Jon Congleton

Yes. Thank you, Tara. We have been obviously focused on appropriately conveying the information about lorundrostat its data set across the spectrum of patients that we've studied, both the parent confirmed from Advance-HTN and our Explore programs. There are, at this stage, multiple guidelines. Our expectation is that certainly at the beginning, it will likely be in that fourth line resistant hypertension. How the guideline committees reflect the ASIs relative to the MRA, some of that is yet to play out, but I think there's obviously compelling clinical evidence to put them on parity. I would say that's where our focus has been with the various guideline committee members.

From a payer standpoint, I think it's informative, but it's not absolute. The payers and the discussions that we've had and even the market research we've done going back several years, the payers acknowledge they've got a real issue in uncontrolled and certainly in resistant hypertension. They understand the implications for the patients on their health care systems and the cost, and that's why I think you're seeing the kind of uptick we anticipated. What you're seeing now with baxdrostat is an acknowledgment of that unmet need. And so again, I think the guidelines will be informative, but not absolute in how the payers make their reimbursement decisions.

Tara Bancroft

Okay. Great. And I just want to clarify one thing just on timing. When you're doing contract negotiations with payers, can you start this during pricing labeling discussions? Or does it solely have to be after approval?

Eric Warren

Yes. We've already started the engagement. We have a pretty good expectation of what payers are looking forward, both from a clinical as well as a contracting perspective. Obviously, we haven't finalized the price yet, so that hasn't been revealed to the payer, but anticipate once we have approval, a relatively quick engagement and to start turning over some of that access in very short term.

Operator

Our next question is from Matthew Caufield with H.C. Wainwright.

Matthew Caufield

What do you view as the top key points to lorundrostat differentiation to help drive the real-world preference at the prospective launch? And separately, can you speak more to the described patient support program? Should that program be fully implemented by the possible launch timing?

Jon Congleton

Yes. Matt, thanks for the questions. I'll address the first one and have Eric address the second. I think the differentiation, I would begin somewhat broadly, and that is we know from meta-analysis with the existing genericized treatments that when you add a third or fourth agent, you typically see a 5- to 6-millimeter mercury reduction in systolic blood pressure. That's why I think our data set is very informative, both in launch and in advance when we look at patients, whether they're on 2 meds or 3 or more, we're seeing very robust reductions, 15 to 19-millimeter absolute reductions in BP, which I think just highlights the fact that when patients get to that third or fourth line and still cannot get to goal, aldosterone is likely the culprit that is still keeping them from their goal. And so I think that's, to me, the big opportunity, again, to really target those 20 million patients.

We've spoken in the past when we think about how does lorundrostat compared to baxdrostat. I think the selectivity in half-life has yielded what we believe to be a very compelling clinical profile, both on systolic blood pressure reduction as well as modest impact on on-target AEs, specifically hyperkalemia, hyponatremia and eGFR change. So we feel that we've got not only compelling data, but breadth of data, again, across apparent confirmed hypertension based on rates that we efforted with intent to have great diversity in the trial with 28% black or African-American in launch and 53% in advanced HTN. And so I think we've got a very compelling argument for physicians somewhat independent of who their patients may be that they're dealing with.

Regarding the patient support program.

Eric Warren

Yes, Matt. In terms of timing, so shortly after launch, you can anticipate that patient support program. And for competitive reasons, I won't get into all the details, but as I did say in the predefined remarks that it's important that it addresses both the HCP as well as their staff and the patients. So as you see the elements of our PSP unfold, don't be surprised to see all 3 of those addressed.

Operator

Our next question is from Alice Nettleton with UBS.

Alice Nettleton

So just assuming FDA approval, how quickly do you expect to launch lorundrostat after the PDUFA date? And then I have a follow-up.

Jon Congleton

Yes. Thanks, Alice. Presuming approval, our goal is to get lorundrostat into the hands of patients and access for physicians as soon as possible. We haven't guided specifically to what that kind of timing would look like. That's something we may provide post PDUFA date, but we haven't guided to that yet.

Alice Nettleton

And then again, on the AstraZeneca 3Q number, I think that's the main focus of investors. It kind of implies a low net price in 3Q if you look at the IQVIA data. And assuming this is relating to payer access still developing and the high patient support burden with the access program. I guess lorundrostat will be launching into probably a stronger ASI coverage in 2027. So should we assume you will have a more favorable gross to net at launch? Or will early 2027 still be challenging?

Eric Warren

Yes, Alice, it's Eric. So still really early. And as you mentioned, a combination of rebates and then some of those buydowns that they're doing make it pretty difficult to truly discern where that GTN will land. And then in terms of providing comments about our GTN, probably a little premature to do that. But as I said, that payer engagement has been a priority to us. So making sure that we have that rapid commercial and then obviously are pulling through that Medicare exception process. So not going to speculate on our GTN, but we'll start to reveal those details as we get closer into launch.

Operator

We have reached the end of the question-and-answer session. I would like to turn the floor back over to Jon Congleton for closing comments.

Jon Congleton

Thank you, operator, and thank you all for joining us today.

We are now just weeks away from our December 22 PDUFA target date. Our focus is squarely on being ready to reach patients soon after potential approval. The new data we shared at AHA-HTN and ASN Kidney Week add to the data supporting lorundrostat in uncontrolled or resistant hypertension, and we look forward to presenting long-term data from Transform-HTN open-label extension trial at the American Heart Association Scientific Sessions this coming Sunday. Our commercialization plans are on track. Our engagement with physicians and payers continues, and we look forward to the potential to bring lorundrostat to millions of patients in need.

On behalf of the entire Mineralys team, thank you for your continued interest and support, and we look forward to updating you on our progress.

Operator

This concludes today's teleconference. You may disconnect your lines at this time. Thank you for your participation.